Xeris Biopharma scores FDA approval for endogenous Cushing’s syndrome drug Recorlev
Synopsis -Ahead of its New Year’s Day decision deadline at the FDA, Xeris Biopharma has snagged an approval for Recorlev, a drug…
Synopsis -Ahead of its New Year’s Day decision deadline at the FDA, Xeris Biopharma has snagged an approval for Recorlev, a drug…